Daratumumab was capable to lyse 58.34 ± 0.27% of tumor cells, while isatuximab and #5-CD38-IgG1 showed significant and comparable tumor cell lysis of 30.13 ± 6.58% and 32.43 ± 1.24%, respectively (Figure 6C). Here, CD38 is linked to neoplasm.